Ultrafast 30‐min infusion of a rituximab biosimilar (Truxima)
E Pérez‐Persona, L Cuevas Palomares… - …, 2023 - Wiley Online Library
Ultrafast 30‐min infusion of a rituximab biosimilar (Truxima) - Pérez‐Persona - 2023 - eJHaem -
Wiley Online Library Skip to Article Content Skip to Article Information Wiley Online Library …
Wiley Online Library Skip to Article Content Skip to Article Information Wiley Online Library …
4CPS-303 Efficacy and safety of monotherapy with pembrolizumab in non-microcytic metastatic lung cancer in clinical practice
CV Martín, JJG Albás, MÁA Moralejo, JP Molina… - 2021 - ejhp.bmj.com
Background and importance Pembrolizumab is an anti-PD1 antibody used to treat
metastatic non-small cell lung cancer (m-NSCLC). Aim and objectives To analyse the …
metastatic non-small cell lung cancer (m-NSCLC). Aim and objectives To analyse the …
Txagorrapid: Ultrarapid infusion in 30 minutes of the biosimilar of rituximab truxima—A cohort study.
E Perez Persona, L Cuevas Palomares… - 2022 - ascopubs.org
e13638 Background: Rituximab (anti-CD20 Ab) is the cornerstone of the treatment of non-
Hodgkin B lymphomas. Infusion-related reactions (IRR) are the most common adverse …
Hodgkin B lymphomas. Infusion-related reactions (IRR) are the most common adverse …
4CPS-104 Switching oral antiandrogenic treatment in patients with castrate metastatic prostate cancer: an analysis
CV Martín, JJG Albás, MÁA Moralejo, HA Pérez… - 2020 - ejhp.bmj.com
Background and importance Abiraterone is used in combination with prednisone, is
metabolised by the liver (CYP3A4) and is an enzyme inhibitor (CYP2D6/CYP2C8) …
metabolised by the liver (CYP3A4) and is an enzyme inhibitor (CYP2D6/CYP2C8) …
CP-009 Adequacy of intravenous immunoglobulin prescription at a teaching hospital
MAA Moralejo, JJG Albás, LG Ron… - European Journal of …, 2014 - ejhp.bmj.com
Background Off-label prescription of intravenous immunoglobulin (IVIg) has long been
widely accepted, but periodically, verification with the latest available evidence-based …
widely accepted, but periodically, verification with the latest available evidence-based …
CP-102 Carboplatin–paclitaxel–bevacizumab based treatment for non-small cell lung advanced cancer patients: use review
AM Ayestaran, JJG Albas, GG Gomez… - European Journal of …, 2014 - ejhp.bmj.com
Background Bevacizumab added to carboplatin and paclitaxel is indicated for first-line
treatment in advanced non squamous non-small cell lung cancer (NSCLC) and has been …
treatment in advanced non squamous non-small cell lung cancer (NSCLC) and has been …